About this item:

178 Views | 120 Downloads

Author Notes:

Corresponding author: Kris Ann P. Schultz, MD, Cancer and Blood Disorders Program, Children’s Hospitals and Clinics of Minnesota, 2530 Chicago Ave South, CSC 175, Minneapolis, MN 55404, 612-813-5940, FAX: 612-813-6325, krisAnn.Schultz@childrensmn.org

The authors thank Michelle Roesler, Wendy Leisenring and Pam Goodman for their kind assistance in research coordination and manuscript preparation

The authors also wish to gratefully acknowledge the patients, families and referring physicians who contributed to this work.

Subjects:

Research Funding:

We thank Children’s Cancer Research Fund, Children’s Oncology Group, and the National Cancer Institute (U24CA55727, 5U10 CA07306 and 1R01CA78960) for their support of this research.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Oncology
  • Hematology
  • Pediatrics
  • leukemia
  • Down syndrome
  • quality of life
  • chemotherapy
  • ACUTE LYMPHOBLASTIC-LEUKEMIA
  • NEUROCOGNITIVE OUTCOMES
  • CANCER-GROUP
  • THERAPY
  • PROTOCOLS
  • DIAGNOSIS

Health-related Quality of Life (HR-QOL) and Chronic Health Conditions in Survivors of Childhood Acute Myeloid Leukemia (AML) with Down Syndrome (DS): A Report From the Children's Oncology Group

Tools:

Journal Title:

Journal of Pediatric Hematology/Oncology

Volume:

Volume 39, Number 1

Publisher:

, Pages 20-25

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Survival rates for children with Down syndrome (DS) and acute myeloid leukemia (AML) are high; however, little is known regarding the health-related quality of life (HR-QOL) of these survivors. Individuals who survived Z5 years following diagnosis of childhood AML were invited to complete parent or patient-report surveys measuring HR-QOL and chronic health conditions. In total, 26 individuals with DS had a median age at diagnosis of 1.8 years (range, 0.77 to 10.9 y) and median age at interview of 15 years (range, 8.3 to 27.6 y). Participants with DS and AML were compared with AML survivors without DS whose caregiver completed a HR-QOL survey (CHQ-PF50). In total, 77% of survivors with DS reported Z1 chronic health condition compared with 50% of AML survivors without DS (P=0.07). Mean physical and psychosocial QOL scores for children with DS and AML were statistically lower than the population mean, though not discrepant from AML survivors without DS. Although the overall prevalence of chronic health conditions in survivors with DS is higher than in survivors without DS, prior studies of children with DS have reported similarly high rates of chronic health conditions, suggesting that AML therapy may not substantially increase this risk.

Copyright information:

© 2016 Wolters Kluwer Health, Inc. All rights reserved.

Export to EndNote